2022
012 Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men
Swerdloff R, Honig S, Wang C, Gittelman M, Seo B, Rohowsky N, Dudley R. 012 Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men. The Journal Of Sexual Medicine 2022, 19: s128-s128. DOI: 10.1016/j.jsxm.2022.03.548.Peer-Reviewed Original ResearchTestosterone replacement therapyHypogonadal menOral TUEugonadal rangeSystolic BPSafety profileTrial 2T concentrationsDose-titration trialInjection site painMo of therapyDays of therapyIPSS total scoreLong-term efficacyTrial 1Two-year followMean T concentrationsLong-term extensionPreferred administration routeMen ages 18CV endpointsLFT elevationsALT levelsSite painAE reporting3 Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men
Swerdloff R, Honig S, Wang C, Gittelman M, Seo B, Rohowsky N, Dudley R. 3 Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men. The Journal Of Sexual Medicine 2022, 19: s2-s2. DOI: 10.1016/j.jsxm.2022.01.014.Peer-Reviewed Original ResearchTestosterone replacement therapyHypogonadal menOral TUEugonadal rangeSystolic BPSafety profileTrial 2T concentrationsDose-titration trialInjection site painMo of therapyDays of therapyIPSS total scoreLong-term efficacyTrial 1Two-year followMean T concentrationsLong-term extensionPreferred administration routeMen ages 18CV endpointsLFT elevationsALT levelsSite painAE reporting
2013
1660 INTEGRATED SAFETY PROFILE OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM IN CLINICAL STUDIES EVALUATING THE TREATMENT OF PEYRONIE'S DISEASE
Carson C, Sadeghi-Nejad H, Smith T, Kaufman G, Gilbert K, Honig S. 1660 INTEGRATED SAFETY PROFILE OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM IN CLINICAL STUDIES EVALUATING THE TREATMENT OF PEYRONIE'S DISEASE. Journal Of Urology 2013, 189: e683. DOI: 10.1016/j.juro.2013.02.3074.Peer-Reviewed Original Research